Currently out of the existing stock ratings of Michael Petusky, 249 are a BUY (88.3%), 31 are a HOLD (10.99%), 2 are a SELL (0.71%).

Michael Petusky

Work Performance Price Targets & Ratings Chart

Analyst Michael Petusky, currently employed at BARRINGTON, carries an average stock price target met ratio of 54% that have a potential upside of 27.13% achieved within 247 days.

Michael Petusky’s has documented 619 price targets and ratings displayed on 19 stocks. The coverage is on Healthcare, Consumer Defensive, Technology sectors.

Most recent stock forecast was given on ANIK, Anika Therapeutics at 09-Jan-2026.

Wall Street Analyst Michael Petusky

Analyst best performing recommendations are on VRME (VERIFYME).
The best stock recommendation documented was for VRME (VERIFYME) at 3/29/2023. The price target of $2 was fulfilled within 5 days with a profit of $0.43 (27.39%) receiving and performance score of 54.78.

Average potential price target upside

of $18.88 (15.22%) on VAR (VARIAN MEDICAL SYSTEMS).
of $16.02 (39%) on XRAY (DENTSPLY SIRONA).
of $13.85 (22.4%) on HAE (HAEMONETICS).

ANIK Anika Therapeutics HAE Haemonetics HSIC Henry Schein LMAT LeMaitre Vascular LNDC Landec MMSI Merit Medical Systems OPK Opko Health PRMW Primo Water Corp TVTY Tivity Health USPH US Physicalrapy XRAY Dentsply Sirona MODV ModivCare OPCH Option Care Health SRDX SurModics VAR Varian Medical Systems VRME VerifyMe PI Impinj LFCR Lifecore Biomedical OFIX Orthofix Medical

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score